- Home
- EGBN vs ERAS Comparison
EGBN vs ERAS Comparison
Compare EGBN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGBN
- ERAS
- Stock Information
- Founded
- EGBN 1997
- ERAS 2018
- Country
- EGBN United States
- ERAS United States
- Employees
- EGBN N/A
- ERAS N/A
- Industry
- EGBN Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EGBN Finance
- ERAS Health Care
- Exchange
- EGBN Nasdaq
- ERAS Nasdaq
- Market Cap
- EGBN 737.8M
- ERAS 719.0M
- IPO Year
- EGBN 1998
- ERAS 2021
- Fundamental
- Price
- EGBN $23.10
- ERAS $2.67
- Analyst Decision
- EGBN Hold
- ERAS Strong Buy
- Analyst Count
- EGBN 3
- ERAS 5
- Target Price
- EGBN $24.00
- ERAS $6.00
- AVG Volume (30 Days)
- EGBN 401.7K
- ERAS 1.4M
- Earning Date
- EGBN 10-23-2024
- ERAS 11-07-2024
- Dividend Yield
- EGBN 6.54%
- ERAS N/A
- EPS Growth
- EGBN N/A
- ERAS N/A
- EPS
- EGBN N/A
- ERAS N/A
- Revenue
- EGBN $244,025,000.00
- ERAS N/A
- Revenue This Year
- EGBN N/A
- ERAS N/A
- Revenue Next Year
- EGBN $6.03
- ERAS N/A
- P/E Ratio
- EGBN N/A
- ERAS N/A
- Revenue Growth
- EGBN N/A
- ERAS N/A
- 52 Week Low
- EGBN $15.99
- ERAS $1.51
- 52 Week High
- EGBN $31.97
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- EGBN 50.69
- ERAS 47.54
- Support Level
- EGBN $22.32
- ERAS $2.52
- Resistance Level
- EGBN $25.10
- ERAS $2.94
- Average True Range (ATR)
- EGBN 0.73
- ERAS 0.16
- MACD
- EGBN -0.05
- ERAS 0.02
- Stochastic Oscillator
- EGBN 28.83
- ERAS 49.06
About EGBN Eagle Bancorp Inc.
Eagle Bancorp Inc is a bank holding company that operates through its wholly-owned subsidiary, EagleBank which offers a broad range of commercial banking services to business and professional clients, and consumer banking services to individuals. These services include commercial loans for a variety of business purposes such as for working capital, equipment purchases, real estate lines of credit and government contract financing, asset-based lending and accounts receivable financing, construction and commercial real estate loans, business equipment financing, consumer home equity lines of credit, personal lines of credit and term loans, consumer loans, personal credit cards, residential mortgage loans.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.